The Investor
31 Mar 2026, 14:04
AstraZeneca announced positive Phase III clinical trial results for its investigational therapy efzimfotase alfa (ALXN1850), targeting the rare bone disease hypophosphatasia (HPP).
The global clinical program showed strong results in pediatric patients, with the MULBERRY trial meeting its primary endpoint and demonstrating significant improvements in bone health. The CHESTNUT trial also confirmed favorable safety and tolerability in children switching from existing treatments.
In adolescents and adults, the HICKORY trial did not meet its primary endpoint overall, but showed meaningful benefits in certain subgroups, including improvements in mobility, fatigue, and pain.
Overall, the therapy demonstrated a favorable safety profile across studies and may offer a more convenient dosing regimen compared to current treatments, with the potential to reshape care for this rare disease pending regulatory review.
The global clinical program showed strong results in pediatric patients, with the MULBERRY trial meeting its primary endpoint and demonstrating significant improvements in bone health. The CHESTNUT trial also confirmed favorable safety and tolerability in children switching from existing treatments.
In adolescents and adults, the HICKORY trial did not meet its primary endpoint overall, but showed meaningful benefits in certain subgroups, including improvements in mobility, fatigue, and pain.
Overall, the therapy demonstrated a favorable safety profile across studies and may offer a more convenient dosing regimen compared to current treatments, with the potential to reshape care for this rare disease pending regulatory review.